journal article·2022-12-31Open access

One-pot preparation of nano-scaled magnetic-pectin particles (Fe3O4@pectin NPs): cytotoxicity, antioxidant, and anti-liver cancer properties

Qiao Zhang, Wenyu Cui, Honglin Guo, Baoqing Wang, He Wang, Jimei Zhang, Wenlan Li

Abstract

This work described the one-pot synthesis of orange pectin encapsulated Fe3O4 nanoparticles (Fe3O4@Pectin NPs) which is prepared by co-precipitation of Fe(II/(III) ions in alkaline solution mediated by pectin. This process led to formation of magnetic nanoparticles within the network of pectin. Physicochemical characterization of the as-synthesized Fe3O4@Pectin NPs was carried out through Fourier transformed infrared spectroscopy (FT-IR), electron microscopy (SEM and TEM), energy dispersive X-ray spectroscopy (EDX), vibrating sample magnetometer (VSM) and X-ray diffraction (XRD). The in vitro cytotoxic and anti-liver cancer effects of biologically synthesized Fe3O4@Pectin NPs against pleomorphic hepatocellular carcinoma (SNU-387), hepatic ductal carcinoma (LMH/2A), morris hepatoma (McA-RH7777), and novikoff hepatoma (N1-S1 Fudr) cancer cell lines were assessed. The anti-liver cancer properties of the Fe3O4@Pectin NPs could significantly remove pleomorphic hepatocellular carcinoma (SNU-387), hepatic ductal carcinoma (LMH/2A), morris hepatoma (McA-RH7777), and novikoff hepatoma (N1-S1 Fudr) cancer cell lines in a time and concentration-dependent manner by MTT assay. The IC50 of the Fe3O4@Pectin NPs were 8, 13, 10, and 7 µg/mL against pleomorphic hepatocellular carcinoma (SNU-387), hepatic ductal carcinoma (LMH/2A), morris hepatoma (McA-RH7777), and novikoff hepatoma (N1-S1 Fudr) cancer cell lines. The antioxidant activity of Fe3O4@Pectin NPs was determined by DPPH method. The Fe3O4@Pectin NPs showed the high antioxidant activity according to the IC50 value. It seems that the anti-human liver cancer effect of recent nanoparticles is due to their antioxidant effects.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmacy, Harbin University of Commerce, Harbin, Heilongjiang, China

Department of Interventional, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China

Biology College, The Ohio State University, Columbus, Ohio, USA

Funding

research and development plan guidance

References (39)

Show source-provided references
1. Stewart B, Wild CP, World Cancer Report 2014. International Agency for Research on Cancer World Health Organization; Lyon, France; 2014. Available online: http://www.iarc.fr/en/publications/books/wcr/wcr-order.php.
2. 10.1517/17425247.2010.50256010.1517/17425247.2010.502560 ↗
3. 10.1016/j.msec.2014.04.04910.1016/j.msec.2014.04.049 ↗
4. 10.1016/j.jconrel.2015.05.00310.1016/j.jconrel.2015.05.003 ↗
5. 10.1016/j.bcp.2014.08.01510.1016/j.bcp.2014.08.015 ↗
6. 10.1016/j.carbpol.2020.11596610.1016/j.carbpol.2020.115966 ↗
7. 10.1016/j.matlet.2018.01.01410.1016/j.matlet.2018.01.014 ↗
8. 10.1007/s11060-010-0389-010.1007/s11060-010-0389-0 ↗
9. 10.1021/nn405356r10.1021/nn405356r ↗
10. 10.1007/s11095-010-0318-010.1007/s11095-010-0318-0 ↗
11. 10.2217/nnm.12.11210.2217/nnm.12.112 ↗
12. 10.1016/j.nano.2014.07.00710.1016/j.nano.2014.07.007 ↗
13. 10.1016/j.biomaterials.2008.09.04410.1016/j.biomaterials.2008.09.044 ↗
14. Silva AC · Int J Nanomed · 2011 · 6 · 591
15. 10.3109/0265673100374574010.3109/02656731003745740 ↗
16. 10.1016/j.rpor.2013.09.01110.1016/j.rpor.2013.09.011 ↗
17. 10.1021/jp502622410.1021/jp5026224 ↗
18. 10.1016/j.addr.2008.08.00310.1016/j.addr.2008.08.003 ↗
19. 10.3748/wjg.v10.i21.319110.3748/wjg.v10.i21.3191 ↗
20. 10.1016/j.nano.2008.04.00110.1016/j.nano.2008.04.001 ↗
21. 10.1016/j.nano.2010.01.01010.1016/j.nano.2010.01.010 ↗
22. 10.1016/j.nano.2012.10.01010.1016/j.nano.2012.10.010 ↗
23. 10.1021/nl052024f10.1021/nl052024f ↗
24. 10.1007/s12013-014-0386-610.1007/s12013-014-0386-6 ↗
25. 10.1038/nrd355410.1038/nrd3554 ↗
26. 10.1002/smll.20060048810.1002/smll.200600488 ↗
27. 10.1021/nn506107c10.1021/nn506107c ↗
28. 10.1021/nn304872n10.1021/nn304872n ↗
29. 10.1021/nn503450t10.1021/nn503450t ↗
30. 10.1039/C4TB01169D10.1039/C4TB01169D ↗
31. 10.1038/nnano.2006.9110.1038/nnano.2006.91 ↗
32. 10.1016/j.biomaterials.2006.11.03610.1016/j.biomaterials.2006.11.036 ↗
33. 10.1039/b615134e10.1039/b615134e ↗
34. 10.1021/ja056726i10.1021/ja056726i ↗
35. 10.1002/aoc.524610.1002/aoc.5246 ↗
36. 10.1016/j.jphotobiol.2019.01.01710.1016/j.jphotobiol.2019.01.017 ↗
37. 10.1139/v90-34810.1139/v90-348 ↗
38. 10.1016/j.jphotobiol.2018.05.01610.1016/j.jphotobiol.2018.05.016 ↗
39. 10.1016/S0927-7765(03)00151-610.1016/S0927-7765(03)00151-6 ↗